Le Lézard
Classified in: Covid-19 virus

The Worldwide Heparin Industry is Expected to Reach $10 Billion by 2027 - ResearchAndMarkets.com


The "Global Heparin Market By Type, By Application, By Route of Administration, By End Use, By Regional Outlook, COVID-19 Impact Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

The Global Heparin Market size is expected to reach $10 billion by 2027, rising at a market growth of 6.5% CAGR during the forecast period.

Companies Profiled

Heparin is also called unfractionated heparin (UFH). It refers to a glycosaminoglycan that naturally forms in the body. Heparin is widely used as an anticoagulant in medicine that acts as a blood thinner. Thus, it finds its application in the treatment of unstable angina and heart attacks. It can either injected into a vein or under the skin. Acute coronary syndrome, pulmonary embolism, atrial fibrillation, deep vein thrombosis, cardiopulmonary bypass & hemofiltration during cardiac surgery can be treated by the use of heparin. Nowadays, it is also used in major orthopedic surgeries like hip and knee replacements.

As per the data published by the Centers for Disease Control and Prevention (CDC) in 2018, it is estimated that more than 900,000 people in the U.S. are suffering from pulmonary embolism and deep vein thrombosis every year. This factor is anticipated to boost the regional demand in the forecast period. The geriatric population is at greater risk of various chronic diseases like deep vein thrombosis and pulmonary embolism. The increasing incidences of chronic diseases will positively influence the expansion of the heparin market across the globe. Moreover, the introduction of highly precise and upgraded heparin products by the market players will boost the growth of the heparin market.

COVID-19 Impact

The sudden outbreak of COVID-19 has adversely affected the healthcare sector. It has disrupted workflows in the health care system all across the globe. Due to this viral disease, a number of industries were forced to shut their doors temporarily. It also includes several subdomains of health care. However, it has a positive effect on the heparin market as there is a surge in demand for various medical services. A large number of patients who are suffering from COVID-19, their lungs are severely affected as it is a respiratory disease. The demand for heparin has been increased during the pandemic as it is used to control respiratory inflation. It causes thinning of the blood and reduces the risk of a blood clot.

Anticoagulant medications also include low molecular weight heparins which are well-tolerated and they have fewer side effects. Irrespective of risk ratings, patients who get admitted to the hospital with COVID-19 infection are treated with prophylactic-dose of low molecular weight heparin. In the suspected COVID-19 infected patients, a baseline chest CT scan is performed and they are needed to be admitted to the hospital. Various scientific studies revealed that the LMW heparin is capable of binding with SARS-CoV-2 Spike protein. So, it can be used as an effective therapeutic approach to reduce thrombosis and pulmonary embolism complications that arise in SARS-CoV-2 patients. As a result, heparin can be used in the treatment of COVID-19 patients. Though, various clinical studies & development are in progress to improve LMWH's efficacy.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

2.1 Introduction

2.1.1 Overview

2.1.2 Market composition and scenario

2.2 Key Factors Impacting the Market

2.2.1 Market Drivers

2.2.2 Market Restraints

Chapter 3. Global Heparin Market by Type

3.1 Global Low Molecular Weight Heparin Market by Region

3.2 Global Unfractionated Heparin Market by Region

3.3 Global Ultra-low Molecular Weight Heparin Market by Region

Chapter 4. Global Heparin Market by Application

4.1 Global Atrial Fibrillation Market by Region

4.2 Global Coronary Artery Disease Market by Region

4.3 Global Venous Thromboembolism Market by Region

4.4 Global Renal Impairment Market by Region

4.5 Global Other Applications Market by Region

Chapter 5. Global Heparin Market by Route of Administration

5.1 Global Subcutaneous Market by Region

5.2 Global Intravenous Market by Region

Chapter 6. Global Heparin Market by End Use

6.1 Global Outpatient Market by Region

6.2 Global Inpatient Market by Region

Chapter 7. Global Heparin Market by Region

7.1 North America Heparin Market

7.1.1 North America Heparin Market by Type

7.1.1.1 North America Low Molecular Weight Heparin Market by Country

7.1.1.2 North America Unfractionated Heparin Market by Country

7.1.1.3 North America Ultra-low Molecular Weight Heparin Market by Country

Chapter 8. North America Heparin Market by Application

Chapter 9. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/e0d3ow


These press releases may also interest you

at 00:01
Russia's invasion of Ukraine is testing the capacity of global food systems to feed the world in times of crisis....

16 mai 2022
Robbins Geller Rudman & Dowd LLP announces that purchasers of Oscar Health, Inc. Class A common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Oscar...

16 mai 2022
The latest market outlook report titled "Publishing Market by Platform and Geography - Forecast and Analysis 2022-2026" has been added to Technavio's catalog. This recent market analysis report identifies the market to witness a potential growth...

16 mai 2022
The latest market outlook report titled "Hand Hygiene Market by End-user and Geography - Forecast and Analysis 2022-2026" has been added to Technavio's catalog. This recent market analysis report identifies the market to witness a potential growth...

16 mai 2022
Trees...

16 mai 2022
Mydecine Innovations Group Inc. (NEO: MYCO) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results and provided a business update for the...



News published on 20 january 2022 at 11:25 and distributed by: